Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Drug utilisation

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Multicentre, European, observational
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

SODIUM SULPHATE
MAGNESIUM SULFATE HEPTAHYDRATE
POTASSIUM SULPHATE
Population studied

Short description of the study population

Patients who were eligible for colon preparation with BLI800 (Eziclen®/Izinova®) and provide written informed consent.
Patients were enrolled from specialised gastroenterology and hepatogastroenterology hospitals/clinics and endoscopy centres and might be inpatients or outpatients.
All patients must fulfil the following criteria:
• They are eligible for a prescription of BLI800 (Eziclen®/Izinova®) as a cleansing bowel preparation in accordance with the marketing authorisation And
• They sign the ICF.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Hepatic impaired
Renal impaired

Estimated number of subjects

1285
Study design details

Main study objective

The objective of this study is to assess drug utilisation in the real life setting in a representative sample of the European target population.

Outcomes

Primary objective is to document the misuse of BLI800 (Eziclen®/Izinova®), defined as non-compliance in terms of insufficient liquid intake, during the postapproval period in the real life setting. Secondary objective is to describe the safety profile of BLI800 (Eziclen®/Izinova®) in routine clinical practice, overall and in case of misuse defined as non-compliance in terms of insufficient liquid intake, and identify any immediate/acute adverse events associated with the use of BLI800 (Eziclen®/Izinova®) in special populations (i.e. the elderly and patients at risk of electrolyte shifts).

Data analysis plan

Sample size is based on the primary endpoint that is to say the proportion of non-compliant patients defined as having taken less than 75% of the prescribed hydration volume (2 L). The sample size for special population should represent 30% of the recruited patients. Assuming a proportion of 50%, this sample size will allow estimating the proportion with a 2- sided 95% level of confidence and a precision of +/- 5%. The total included population will represent 1285 patients.Each site will be required to offer enrolment to consecutive patients requiring bowel cleansing prior to colonoscopy and eligible for BLI800 (Eziclen®/Izinova®) in accordance with the marketing authorisation. All eligible patients at each study centre will be offered enrolment, until 65 patients are enrolled per site. However, the actual numbers will depend on the drug uptake following launch.
Documents
Study results
English (2.87 MB - PDF)View document